The below items are just my thoughts , I dont know how accurate these points are
1) if CIAB platform works for oncology , diabetes, human and veterinary , then the platform may be valuable to a Big P . I expect the big P would want total control and buy PMCB + SGA + have a new agreement with Bavarian Nordic for the rights to the special SCS (sodium cellulose sulfate material which makes up CIAB capsules)
2) pmcb HAS APPLIED FOR A NEW PATENT ( Spring 2017) FOR CIAB + P450 genetically modified cells for treatment to activate a pro-drug to treat solid tumors ... I do not know the status of this patent ,
but I suppose we do have orphan drug designation to protect our treatment exclusivity for 7 years / 10 years in Europe
3) PMCB has "X" number of years to make clinical use of CIAB , otherwise rights revert back to SGA and Bavarian Nordic
4) I am not sure , but I believe the SCS sodium cellulose sulfate material may no longer be patent protected , and that PMCB no longer owes any payment to Bavarian Nordic
5) maybe Yuen ( PrimeGen) will see a real possibility with CIAB platform , and PMCB + SGA will agree to M&A with Yuen , re-structured , and up-list to NASDQ after a successful Pivotal Trial , and plan to fulfill the treatment demand for product , to treat all solid tumors
6) re Diabetes, it does seem as though encapsulated cells are the next big improvement for treatment . Harvard has developed stem cells , and we have our Melligen cells , Regardless of wjhich cell type works best , and lives the longest , it seems our SCS cotton micro capsules are the best thing going for beating the immune response .
Market Data 
Markets 
AI
